Second win for Myriad as Federal Circuit stands firm on gene patent ruling

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Second win for Myriad as Federal Circuit stands firm on gene patent ruling

solated-dna-molecule-on-white-background-45.jpg

Biotech company Myriad, which owns US patents covering the isolation and detection of the BRCA1 and BRCA2 genes, has won a second victory at the US Court of Appeals for the Federal Circuit

In the long-running dispute, a number of parties including the Association for Molecular Pathology argued that Myriad’s claims covered matter that was not eligible for patent protection.

In today’s majority opinion, Judge Alan Lourie affirmed that the district court had declaratory judgment jurisdiction as at least one plaintiff (Harry Ostrer) had standing to challenge the validity of the patents.

The Federal Circuit also again reversed the district court’s finding that Myriad’s composition claims to isolated DNA molecules cover patent-ineligible products of nature saying “each of the claimed molecules represents a nonnaturally occurring composition of matter”

In addition, the court reversed the finding that Myriad’s method claim to screening potential cancer therapeutics via changes in cell growth rates of transformed cells is directed to a patent-ineligible scientific principle.

But it affirmed the district court’s decision that Myriad’s method claims directed to “comparing” or “analyzing” DNA sequences are patent ineligible, saying “such claims include no transformative steps and cover only patent-ineligible abstract, mental steps”.

Judge Kimberly Moore, who reportedly asked probing questions in the oral hearing, wrote a concurring opinion.

But Judge William Bryson wrote an opinion in which he dissented from the court’s holding that Myriad’s BRCA gene claims and its claims to gene fragments are patent-eligible.

“In my view, those claims are not directed to patentable subject matter, and the court’s decision, if sustained, will likely have broad consequences, such as preempting methods for whole-genome sequencing, even though Myriad’s contribution to the field is not remotely consonant with such effects,” wrote Bryson.

The Federal Circuit first ruled in the Myriad case in July last year, after which an appeal to the Supreme Court was filed. The case was remanded back to the Federal Circuit following the Supreme Court’s decision in Mayo v Prometheus in March this year.

The list of attorneys acting for the parties and amicus curiae extends to five pages of the opinion. One of them was Dan Ravicher of the Public Patent Foundation, who was profiled as one of the 50 most influential people in IP last month.

Managing IP also has a page devoted to the Myriad case.

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article